🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Nina Raben

National Institutes of Health

ORCID: 0000-0001-9519-3535

Also affiliated with National Heart Lung and Blood Institute

MedicineChemistryBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 10 papers. Top paper: “Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease”.

Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease

EMBO Molecular Medicine(2013)10.1002/emmm.201202176
N/A
0.873DataRank · unranked
337 citations

Erin Feeney, Lishu Li, Monica Cardone, Jeong‐A Lim, Fabio Annunziata +7 more

Impaired autophagy: The collateral damage of lysosomal storage disorders

EBioMedicine(2020)10.1016/j.ebiom.2020.103166
N/A
0DataRank · unranked
74 citations

Rosa Puertollano, Nina Raben, Rachel Myerowitz

SnapShot: Lysosomal Storage Diseases

Cell(2020)10.1016/j.cell.2020.01.017
N/A
0DataRank · unranked
49 citations

Nina Raben, Rosa Puertollano, José A. Martina

Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease

Molecular Therapy — Methods & Clinical Development(2020)10.1016/j.omtm.2020.05.026
N/A
0DataRank · unranked
40 citations

Evelyn Ralston, Nina Raben, Rosa Puertollano, Naresh Kumar Meena

Chemoenzymatic glycan-selective remodeling of a therapeutic lysosomal enzyme with high-affinity M6P-glycan ligands. Enzyme substrate specificity is the name of the game

Chemical Science(2021)10.1039/d1sc03188k
N/A
0DataRank · unranked
11 citations

Hui‐Ying Liu, Naresh Kumar Meena, Chao Li, Guanghui Zong, Nina Raben +3 more

Pompe Disease: New Developments in an Old Lysosomal Storage Disorder

Biomolecules(2020)10.3390/biom10091339
N/A
0DataRank · unranked
112 citations

Nina Raben, Naresh Kumar Meena

Intravital imaging of muscle damage and response to therapy in a model of Pompe disease

Clinical and Translational Medicine(2024)10.1002/ctm2.1561
N/A
0DataRank · unranked
3 citations

Yeap Ng, Davide Randazzo, Roberto Weigert, Rosa Puertollano, Nina Raben +1 more

Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.22.580414
N/A
0DataRank · unranked
1 citations

Michele Carrer, Alyaa Shmara, Cheng Cheng, Hong Yin, Lac Ta +13 more

Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease

Clinical and Translational Medicine(2025)10.1002/ctm2.70314
N/A
0DataRank · unranked
1 citations

Michele Carrer, Alyaa Shmara, Ángela M Martin, Hong Yin, Pallabi Pal +14 more

AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice

JCI Insight(2023)10.1172/jci.insight.170199
N/A
0DataRank · unranked
14 citations

Davide Randazzo, Nina Raben, Rosa Puertollano, Naresh Kumar Meena